| h-13ea09f59f | Basal forebrain NGF/TrkA trophic failure is an upstream trigger that makes choli | 0.61 | 0.65 | NGF, NTRK1, APP | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-e849205bca |
| h-80b5226d73 | ALS-Associated G3BP1 Mutations Shift Phase Separation Equilibrium Toward Aberran | 0.61 | 0.70 | G3BP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |
| h-42f8fa19eb | Age-Accelerated miR-155 Upregulation Primes Nigral Microglia for Parkinson's Dis | 0.61 | 0.68 | miR-155 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-ec89b1e4 |
| h-32b2bb56c8 | Aberrant Galectin-3 Expression on Stressed Synapses Creates Bridging Molecules | 0.61 | 0.60 | LGALS3 (Galectin-3) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-0b67a9f249 | Microglial priming is primarily epigenetic, with metabolic changes acting as cou | 0.61 | 0.58 | KDM6B | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062033-839c3e2a |
| h-96772461 | Ketone-Based Metabolic Switching to Restore PV Interneuron Function | 0.61 | 0.62 | SIRT3, PVALB | promoted | 2026-04-16 | SDA-2026-04-16-gap-20260416-133111 |
| h-1775578a | Temporal TFEB Modulation Therapy | 0.61 | 0.30 | TFEB | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| h-4b517512 | The Glial Ketone Metabolic Shunt Hypothesis | 0.61 | 0.50 | HMGCS2 | proposed | 2026-04-02 | SDA-2026-04-02-gap-v2-5d0e3052 |
| h-1f3f0de239 | Perturbation-first validation should precede therapeutic claims for Cell-Autonom | 0.61 | 0.55 | ALS | proposed | 2026-04-28 | 687fb884-6d31-47c3-a83f-074bad980db6 |
| h-f9c6fa7676 | Perturbation-first validation should precede therapeutic claims for CCL2-CCR2 Ax | 0.61 | 0.55 | ALS | proposed | 2026-04-28 | f7f8019f-08f6-428b-adff-85e8ea202b60 |
| h-0d597b942f | Perturbation-first validation should precede therapeutic claims for m6A RNA Modi | 0.61 | 0.55 | N6- | proposed | 2026-04-28 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| h-fe626fcf62 | Perturbation-first validation should precede therapeutic claims for Non-Neuronal | 0.61 | 0.55 | | proposed | 2026-04-28 | db9a224d-3ebb-429c-8f02-b703d71ca211 |
| h-3b12dd77de | Perturbation-first validation should precede therapeutic claims for Sex-Specific | 0.61 | 0.55 | | proposed | 2026-04-28 | dfb32151-9c40-452d-8063-0c57bae5c3d6 |
| h-532333955e | Perturbation-first validation should precede therapeutic claims for DPP6 GWAS Si | 0.61 | 0.55 | | proposed | 2026-04-28 | 457c5bc3-21d8-42a3-bb99-b0fc6f3f9554 |
| h-e128d575e8 | Perturbation-first validation should precede therapeutic claims for VEGF Family | 0.61 | 0.55 | VEGF- | proposed | 2026-04-28 | a7f528aa-20c4-409d-a8c3-e2662850e63d |
| h-9b0771a001 | Perturbation-first validation should precede therapeutic claims for Proteogenomi | 0.61 | 0.55 | | proposed | 2026-04-28 | 8ec36980-febb-4093-a5a1-387ea5768480 |
| h-84566f4d8e | Perturbation-first validation should precede therapeutic claims for Causal Seque | 0.61 | 0.55 | | proposed | 2026-04-28 | 0ed3c364-07fd-4620-8e90-8bd33c14e370 |
| h-c34258ddeb | Perturbation-first validation should precede therapeutic claims for Biophysical | 0.61 | 0.55 | RNA | proposed | 2026-04-28 | 52661eaf-79f8-4647-8f48-3389f5af4d59 |
| h-3b6e6d44d5 | Perturbation-first validation should precede therapeutic claims for Genetic Agin | 0.61 | 0.55 | | proposed | 2026-04-28 | bf5094c7-8ae0-4331-9871-d6f3078387c5 |
| h-3489a7e232 | Calmodulin isoform switching from CaMK to calcineurin activation upon lysosomal | 0.61 | 0.58 | CALM1/CALM2/CALM3 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-387cb0ba |
| h-d3a64f5c | Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Fun | 0.61 | 0.20 | DDC | proposed | 2026-04-02 | SDA-2026-04-01-gap-20260401-225149 |
| h-95a1adb645 | CSF ApoE- and clusterin-rich lipoprotein particles stabilize disease-relevant al | 0.61 | 0.57 | APOE | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260411-081644-1d2624b8-debate |
| h-9d4571a7 | Circadian-Gated Ketone Window Hypothesis | 0.61 | 0.30 | OXCT1 | proposed | 2026-04-16 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-722ec547 | TREM2-Mediated Microglial Checkpoint Therapy | 0.61 | 0.60 | TREM2 | proposed | 2026-04-12 | SDA-2026-04-03-gap-seaad-20260402025452 |
| h-4578eac0a3 | P2RY12-mediated autophagy inhibition in cerebral VSMCs impairs CAA clearance | 0.60 | 0.68 | P2RY12 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-d7920f3b |
| h-SDA-2026-04-26-gap | Sigma-1 Receptor-Mediated UPR Reset as Primary Disease-Modifying Mechanism of Tr | 0.60 | 0.43 | SIGMAR1, PERK/eIF2alpha axis, BiP/GRP78 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb |
| h-70b7467628 | c-Abl Tyrosine Kinase Activation Drives α-Synuclein Phosphorylation and Neurodeg | 0.60 | 0.68 | ABL1 | proposed | 2026-04-26 | legacy-pre-pipeline-import-v1 |
| h-4ed1b5a7 | HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM Transition | 0.60 | 0.70 | HK2 | promoted | 2026-04-16 | SDA-2026-04-16-gap-debate-20260410-112642-fffdca96 |
| h-80127a2861 | whether the Mitochondrial transfer between neurons and glia — Rich Analysis Note | 0.60 | 0.57 | Methodology | proposed | 2026-04-28 | SDA-2026-04-27-gap-methodol-20260427-035148-7b3b3df4 |
| h-c843352776 | TREM2 enhancement as a way to restore protective microglial response and reduce | 0.60 | 0.57 | TREM2 | proposed | 2026-04-28 | AD-MASTER-PLAN-TREM2-20260428030753 |
| h-3f36a225e6 | BDNF-mediated hippocampal synaptic rescue as a modifier of CA3-CA1 vulnerability | 0.60 | 0.57 | BDNF | proposed | 2026-04-28 | AD-MASTER-PLAN-BDNF-20260428030755 |
| h-51d64b2310 | GFAP-positive reactive astrocyte states as mediators of regional metabolic vulne | 0.60 | 0.57 | GFAP | proposed | 2026-04-28 | AD-MASTER-PLAN-GFAP-20260428030756 |
| h-1f256c628c | microglial priming as a partially upstream causal node rather than a pure diseas | 0.60 | 0.57 | TREM2 | proposed | 2026-04-28 | SDA-2026-04-28-microglial-priming-causal-nd |
| h-13dc63ff74 | whether debate-structured causal reasoning improves calibration over direct LLM | 0.60 | 0.57 | SciDEX | proposed | 2026-04-28 | SDA-causal-benchmark-20260428-035713 |
| h-d949802674 | whether the Astrocyte reactivity subtypes in neurodegeneration — Rich Analysis N | 0.60 | 0.57 | Methodology | proposed | 2026-04-28 | SDA-2026-04-27-gap-methodol-20260427-035148-9ab1842d |
| h-7a3aba26c2 | APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD patho | 0.60 | 0.57 | APOE | proposed | 2026-04-28 | AD-MASTER-PLAN-APOE-20260428030754 |
| h-4d0a57d392 | LRP1-mediated tau uptake disruption as an initiator of early tau propagation req | 0.60 | 0.57 | LRP1 | proposed | 2026-04-28 | AD-MASTER-PLAN-LRP1-20260428030757 |
| h-e7bcf399bb | whether the Mitochondrial transfer between neurons and glia — Rich Analysis Note | 0.60 | 0.57 | Methodology | proposed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-035148-7b3b3df4 |
| h-1da06f38 | DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabili | 0.60 | 0.68 | DAPK1 | promoted | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260410-100455-ff18091d |
| h-2ff49342 | TREM2-Microglial Clearance Enhancement as Common Mechanism for Injury Prevention | 0.60 | 0.58 | TREM2 | proposed | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-184233-98bf553f |
| h-caa5f7e2 | Impaired TFEB/TFE3 Nuclear Translocation Due to mTORC1 Hyperactivity in Motor Ne | 0.60 | 0.65 | mTORC1-TFEB/TFE3 axis, CLEAR gene network | proposed | 2026-04-26 | SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c |
| h-var-d749cd28cb | Closed-loop transcranial alternating current stimulation to restore hippocampal- | 0.60 | 0.83 | SST | promoted | 2026-04-05 | SDA-2026-04-03-26abc5e5f9f2 |
| h-63a958ab | NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/SIRT1 Activator for | 0.60 | 0.62 | SIRT1 | proposed | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-86d0aa1ede | Rutin reduces ROS- and metal-driven tau oligomer nucleation | 0.60 | 0.51 | MAPT | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260411-085530-9015d285-debate |
| h-6f30a803 | Selective TFEB Cofactor Enhancement | 0.60 | 0.40 | TFE3 | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| h-ed960965 | STING Antagonism Prevents Acute-to-Chronic Neuroinflammation Transition via Inte | 0.60 | 0.65 | TMEM173 (STING) | promoted | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-075425-2feffb0c |
| h-4dd0d19b | LRP1-Dependent Tau Uptake Disruption | 0.60 | 0.49 | LRP1 | archived | 2026-04-02 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-5a50ce127718 | Domain boundary cross-talk hypothesis | 0.60 | 0.60 | MAP6 | proposed | 2026-04-25 | |
| h-765d457dc3 | Autophagy Activation ULK1/VPS34 (H3): Lipid Routing to Lysosomes | 0.60 | 0.72 | ULK1 (autophagy initiation kinase) | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-180918-962b1ada-debate |
| 738bdd16-d947-4758-b | Manual uptake test | 0.60 | 0.37 | | proposed | 2026-04-27 | |